Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab and SBRT for Cisplatin-Ineligible MIBC
By Raj Satkunasivam, MD, MS, FRCSC - Last Updated: August 9, 2023Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, details the RAD VACCINE MIBC trial, a single-arm, phase 2 evaluation of the efficacy and safety of combination neoadjuvant sasanlimab with stereotactic body radiotherapy as an in situ vaccine in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
In his previous comments, Dr. Satkunasivam highlighted traditional treatment approaches for MIBC and the current momentum for an immunotherapy-plus-radiation strategy.
View Dr. Satkunasivam’s previous comments.
Related Posts
Dr. McKiernan provided the argument for surveillance in the event of complete clinical response after NAC for MIBC.
Recent data suggest good quality of life outcomes for patients with muscle-invasive bladder cancer after trimodality therapy.
Pembrolizumab with CRT is a feasible treatment option for MIBC with promising CR rates and manageable toxicity.
Researchers used whole-genome sequencing and a 152-gene panel to study the DNA of patients with high-risk UTUC.
Enfortumab vedotin shows promising activity and tolerability in cisplatin-ineligible patients with MIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.